Capricor Therapeutics: FDA Advisory Committee Votes Against Deramiocel

What Happened

• On July 29, 2026, the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted that the available evidence did not support the effectiveness of Capricor's investigational therapy Deramiocel for treating cardiomyopathy in patients with Duchenne muscular dystrophy (vote: 3 for, 9 against, 0 abstain).
• The committee's recommendation is non-binding; the FDA will consider it along with the complete administrative record as it continues review of Capricor's Biologics License Application (BLA). The FDA's PDUFA target action date for the BLA remains August 22, 2026.
• Capricor issued a press release on July 30, 2026 providing an update on the Advisory Committee meeting and filed an 8-K to report the event.

Key Details

• Advisory Committee vote tally: 3 in favor, 9 opposed, 0 abstentions (July 29, 2026).
• Regulatory status: BLA under FDA review; PDUFA target action date is August 22, 2026.
• Drug/indication: Deramiocel for cardiomyopathy in Duchenne muscular dystrophy (a rare, life‑threatening condition with no approved cardiomyopathy treatment).
• Company communication: press release issued July 30, 2026 announcing the Committee vote.

Why It Matters

• A negative advisory committee vote is a material regulatory setback because advisory panels often influence FDA decisions; however, the vote is not binding and the FDA may still approve, request more data, or take other actions by the PDUFA date.
• For investors, the August 22, 2026 PDUFA date is the next key milestone — the FDA decision could have a major impact on Capricor's prospects and share value. In the near term, expect increased regulatory uncertainty until the FDA issues its final action.